Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in Haematologica

Retrieve available abstracts of 129 articles:
HTML format

Single Articles

    June 2022
  1. KWON M, Iacoboni G, Reguera JL, Corral LL, et al
    Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
    Haematologica. 2022 Jun 30. doi: 10.3324/haematol.2022.280805.
    PubMed     Abstract available

  2. FUJI S, Yasunaga JI, Watanabe E, Matsuoka M, et al
    Pseudo-progression of adult T-cell leukemia-lymphoma after cord blood transplantation.
    Haematologica. 2022 Jun 23. doi: 10.3324/haematol.2022.281175.
    PubMed     Abstract available

  3. ISAEV K, Liu T, Bakhtiari M, Tong K, et al
    In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program.
    Haematologica. 2022 Jun 23. doi: 10.3324/haematol.2022.280900.
    PubMed     Abstract available

  4. VELOZA L, Cavalieri D, Missiaglia E, Ledoux-Pilon A, et al
    Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.
    Haematologica. 2022 Jun 16. doi: 10.3324/haematol.2022.281226.
    PubMed     Abstract available

  5. GALTIER J, Vercellino L, Chartier L, Olivier P, et al
    PET-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T-cells.
    Haematologica. 2022 Jun 9. doi: 10.3324/haematol.2021.280550.
    PubMed     Abstract available

    May 2022
  6. ROSSI C, Andre M, Dupuis J, Morschhauser F, et al
    High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.
    Haematologica. 2022 May 31. doi: 10.3324/haematol.2021.280004.
    PubMed     Abstract available

  7. MADUGULA KK, Joseph J, DeMarino C, Ginwala R, et al
    Regulation of Human T-cell Leukemia Virus type 1 antisense promoter by Myocyte Enhancer Factor-2C in the context of Adult T-cell leukemia and lymphoma.
    Haematologica. 2022 May 26. doi: 10.3324/haematol.2021.279542.
    PubMed     Abstract available

  8. SARKOZY C, Salles G
    PET-CT before autologous stem cell transplant in follicular lymphoma: coming too late?
    Haematologica. 2022 May 19. doi: 10.3324/haematol.2021.281255.
    PubMed     Abstract available

  9. EYRE TA, Barrington SF, Okosun J, Abamba C, et al
    Impact of PET-CT status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplant.
    Haematologica. 2022 May 19. doi: 10.3324/haematol.2021.280287.
    PubMed     Abstract available

  10. RIGAUD C, Abbou S, Ducassou S, Simonin M, et al
    Profound and sustained response with next generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement.
    Haematologica. 2022 May 19. doi: 10.3324/haematol.2021.280081.
    PubMed     Abstract available

  11. PICOD A, Martino S, Cervera P, Manuceau G, et al
    Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T cell lymphoma.
    Haematologica. 2022 May 5. doi: 10.3324/haematol.2021.280349.
    PubMed     Abstract available

  12. MEI M, Hamadani M, Ahn KW, Chen Y, et al
    Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit.
    Haematologica. 2022;107:1214-1217.

  13. ESCHERICH G, Zur Stadt U, Borkhardt A, Dilloo D, et al
    Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative
    Haematologica. 2022;107:1026-1033.
    PubMed     Abstract available

  14. GAO J, Wang MY, Ren Y, Lwin T, et al
    Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
    Haematologica. 2022;107:1119-1130.
    PubMed     Abstract available

    April 2022
  15. SMELAND K, Holte H, Fagerli UM, Bersvendsen H, et al
    Total late effect burden in long-term lymphoma survivors after highdose therapy with autologous stem-cell transplant and its effect on health-related quality of life.
    Haematologica. 2022 Apr 28. doi: 10.3324/haematol.2021.280413.
    PubMed     Abstract available

  16. ARRIBAS AJ, Napoli S, Cascione L, Sartori G, et al
    Resistance to PI3kappadelta inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.
    Haematologica. 2022 Apr 28. doi: 10.3324/haematol.2021.279957.
    PubMed     Abstract available

  17. CLOSE K, Fitzgibbon J
    KDM4C in GC lymphoma: a new piece of the epigenetic puzzle.
    Haematologica. 2022 Apr 28. doi: 10.3324/haematol.2022.280898.
    PubMed     Abstract available

  18. TANAKA N, Mori S, Kiyotani K, Ota Y, et al
    Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
    Haematologica. 2022 Apr 14. doi: 10.3324/haematol.2021.280352.
    PubMed     Abstract available

    Images from the Haematologica Atlas of Hematologic Cytology: precursor lymphoid neoplasms, cytochemistry and immunocytochemistry.
    Haematologica. 2022;107:781.

  20. CORREIA E, Cha J, Krishnasamy S, O'Donnell M, et al
    A case series of primary cutaneous B-cell lymphomas with atypical presentations: diagnostic and therapeutic challenges.
    Haematologica. 2022;107:1014-1016.

  21. TANAGER KS, Yu J, Chiu BC, Carll TC, et al
    Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulators.
    Haematologica. 2022;107:966-969.

  22. VISENTIN A, Bonaldi L, Rigolin GM, Mauro FR, et al
    The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.
    Haematologica. 2022;107:868-876.
    PubMed     Abstract available

    March 2022
  23. KIM M, Hwang HS, Yoon DH, Chun SM, et al
    Distinct genetic alterations in Burkitt-like lymphoma with 11q aberration and Burkitt lymphoma: a novel case report of composite lymphoma.
    Haematologica. 2022 Mar 31. doi: 10.3324/haematol.2021.280543.
    PubMed     Abstract available

  24. QUIVORON C, Tarabay A, Michot JM, Pages A, et al
    Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B cell lymphoma.
    Haematologica. 2022 Mar 24. doi: 10.3324/haematol.2021.280464.
    PubMed     Abstract available

  25. GARCIA-SANCHO AM, Bellei M, Lopez-Parra M, Gritti G, et al
    Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
    Haematologica. 2022 Mar 24. doi: 10.3324/haematol.2021.279426.
    PubMed     Abstract available

    A BAFFling menage a trois in mantle cell lymphoma.
    Haematologica. 2022 Mar 10. doi: 10.3324/haematol.2022.280721.
    PubMed     Abstract available

  27. DECOMBIS S, Papin A, Bellanger C, Sortais C, et al
    The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.
    Haematologica. 2022 Mar 10. doi: 10.3324/haematol.2021.279800.
    PubMed     Abstract available

  28. DOURTHE ME, Phulpin A, Auperin A, Bosq J, et al
    Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study.
    Haematologica. 2022 Mar 3. doi: 10.3324/haematol.2021.280257.
    PubMed     Abstract available

  29. CANDON S, Lemee V, Leveque E, Etancelin P, et al
    Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas.
    Haematologica. 2022;107:755-758.

    February 2022
  30. BOUARD L, Tessoulin B, Thieblemont C, Bouabdallah K, et al
    Humoral immune-depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma.
    Haematologica. 2022 Feb 17. doi: 10.3324/haematol.2021.279561.
    PubMed     Abstract available

  31. KORONA B, Korona D, Zhao W, Wotherspoon AC, et al
    CCR6 activation links innate immune responses to MALT lymphoma development.
    Haematologica. 2022 Feb 10. doi: 10.3324/haematol.2021.280067.
    PubMed     Abstract available

  32. CASHEN AF, Bartlett NL
    Stem cell transplant for lymphoma - never too late?
    Haematologica. 2022 Feb 3. doi: 10.3324/haematol.2021.280519.
    PubMed     Abstract available

  33. SMITH S
    Too much and not enough: revisiting maintenance rituximab in indolent lymphomas.
    Haematologica. 2022;107:353-354.

    January 2022
  34. WAI CMM, Chen S, Phyu T, Fan S, et al
    Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS.
    Haematologica. 2022 Jan 13. doi: 10.3324/haematol.2021.280003.
    PubMed     Abstract available

  35. KOCH K, Richter J, Hanel C, Huttmann A, et al
    Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/transformation.
    Haematologica. 2022 Jan 13. doi: 10.3324/haematol.2021.279351.
    PubMed     Abstract available

  36. CHEAH CY, Zucca E, Rossi D, Habermann TM, et al
    Marginal zone lymphoma: present status and future perspectives.
    Haematologica. 2022;107:35-43.

  37. QUALLS D, Salles G
    Prospects in the management of patients with follicular lymphoma beyond first-line therapy.
    Haematologica. 2022;107:19-34.
    PubMed     Abstract available

  38. CARTRON G, Trotman J
    Time for an individualized approach to first-line management of follicular lymphoma.
    Haematologica. 2022;107:7-18.
    PubMed     Abstract available

  39. SMITH SM, Salles G
    Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges.
    Haematologica. 2022;107:4-6.

    Images from the Haematologica Atlas of Hematologic Cytology: Sezary syndrome.
    Haematologica. 2022;107:1.

    December 2021
  41. MAROUF A, Cottereau AS, Kanoun S, Deschamps P, et al
    Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance : a French multicenter observational cohort study.
    Haematologica. 2021 Dec 30. doi: 10.3324/haematol.2021.279564.
    PubMed     Abstract available

  42. KIM HT, Baker PO, Parry E, Davids M, et al
    Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation.
    Haematologica. 2021;106:3219-3222.

    November 2021
  43. KOHN M, Delord M, Chbat M, Guemriche A, et al
    A third anti-SARS-Cov2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.
    Haematologica. 2021 Nov 18. doi: 10.3324/haematol.2021.280026.
    PubMed     Abstract available

  44. KUNSTNER A, Witte HM, Riedl J, Bernard V, et al
    Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing.
    Haematologica. 2021 Nov 18. doi: 10.3324/haematol.2021.279631.
    PubMed     Abstract available

  45. ALBERTSSON-LINDBLAD A, Palsdottir T, Smedby KE, Weibull CE, et al
    Survival in mantle cell lymphoma after frontline treatment with Rbendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017.
    Haematologica. 2021 Nov 18. doi: 10.3324/haematol.2021.279037.
    PubMed     Abstract available

  46. STEINER RE, Banchs J, Koutroumpakis E, Becnel M, et al
    Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma.
    Haematologica. 2021 Nov 11. doi: 10.3324/haematol.2021.280009.
    PubMed     Abstract available

    September 2021
  47. CASAGRANDE N, Borghese C, Aldinucci D
    In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases 3D tumor-stroma heterospheroid viability.
    Haematologica. 2021 Sep 9. doi: 10.3324/haematol.2021.279389.
    PubMed     Abstract available

  48. KNORR F, Zimmermann M, Attarbaschi A, Kabickova E, et al
    Dose-adjusted EPOCH-Rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.
    Haematologica. 2021 Sep 9. doi: 10.3324/haematol.2021.278971.
    PubMed     Abstract available

    Preventing central nervous system spread in diffuse large B-cell lymphoma - novel approaches needed.
    Haematologica. 2021;106:2298-2300.

  50. DONG G, Li Y, Lee L, Liu X, et al
    Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1.
    Haematologica. 2021;106:2427-2438.
    PubMed     Abstract available

    August 2021
  51. DUELL J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, et al
    Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Haematologica. 2021 Aug 19. doi: 10.3324/haematol.2021.279802.
    PubMed     Abstract available

  52. KOSTAKOGLU L, Mattiello F, Martelli M, Sehn LH, et al
    Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.
    Haematologica. 2021 Aug 19. doi: 10.3324/haematol.2021.278663.
    PubMed     Abstract available

  53. BASTIDAS TORRES AN, Melchers RC, Van Grieken L, Out-Luiting JJ, et al
    Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma.
    Haematologica. 2021 Aug 12. doi: 10.3324/haematol.263251.
    PubMed     Abstract available

  54. KIM M, Lee JO, Koh J, Kim TM, et al
    A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas.
    Haematologica. 2021;106:2277-2280.

    July 2021
  55. GURION R, Rozovski U, Itchaki G, Gafter-Gvili A, et al
    Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
    Haematologica. 2021 Jul 29. doi: 10.3324/haematol.2021.279216.
    PubMed     Abstract available

  56. LIN RJ, Owens CN, Drill E, Iannotta A, et al
    Prephase rituximab/prednisone therapy and aging-related, pro-inflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
    Haematologica. 2021 Jul 22. doi: 10.3324/haematol.2021.278719.
    PubMed     Abstract available

  57. DODERO A, Guidetti A, Marino F, Tucci A, et al
    Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
    Haematologica. 2021 Jul 22. doi: 10.3324/haematol.2021.278638.
    PubMed     Abstract available

  58. STRATI P, De Vos S, Ruan J, Maddocks KJ, et al
    Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase 1b study.
    Haematologica. 2021 Jul 8. doi: 10.3324/haematol.2021.278654.
    PubMed     Abstract available

  59. RAM R, Grisariu S, Shargian-Alon L, Amit O, et al
    Toxicity and efficacy of chimeric antigen receptor T-cell in patients with diffuse large B cell lymphoma above the age of 70 years compare to younger patients - a matched control multi-center cohort study.
    Haematologica. 2021 Jul 8. doi: 10.3324/haematol.2021.278288.
    PubMed     Abstract available

  60. DUELL J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, et al
    Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Haematologica. 2021 Jul 1. doi: 10.3324/haematol.2020.275958.
    PubMed     Abstract available

    June 2021
  61. BENKLI CY, Marcogliese AN, Agrusa JE, Adesina AM, et al
    Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients.
    Haematologica. 2021 Jun 24. doi: 10.3324/haematol.2021.278936.
    PubMed     Abstract available

  62. EVENS AM, Connors JM, Younes A, Ansell SM, et al
    Older patients (aged >/=60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
    Haematologica. 2021 Jun 24. doi: 10.3324/haematol.2021.278438.
    PubMed     Abstract available

  63. NAPOLI S, Cascione L, Rinaldi A, Spriano F, et al
    Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma.
    Haematologica. 2021 Jun 24. doi: 10.3324/haematol.2020.267096.
    PubMed     Abstract available

  64. RULE S, Barreto WG, Briones J, Carella AM, et al
    Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the Phase III MabCute study.
    Haematologica. 2021 Jun 17. doi: 10.3324/haematol.2020.274803.
    PubMed     Abstract available

  65. PECE R, Tavella S, Costa D, Varesano S, et al
    Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.
    Haematologica. 2021 Jun 10. doi: 10.3324/haematol.2021.278469.
    PubMed     Abstract available

  66. SVOBODA J, Bair SM, Landsburg DJ, Dwivedy Nasta S, et al
    Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
    Haematologica. 2021;106:1705-1713.
    PubMed     Abstract available

    May 2021
  67. DLOUHY I, Armengol M, Recasens-Zorzo C, Ribeiro ML, et al
    Interleukin-1 receptor associated kinase 1/4 and bromodomain and extraterminal inhibitions converge on NF-kappaB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88(L265P) mutati
    Haematologica. 2021 May 13. doi: 10.3324/haematol.2020.278258.
    PubMed     Abstract available

  68. PILERI SA, Mazzara S, Derenzini E
    Plasmablastic lymphoma: one or more tumours?
    Haematologica. 2021 May 6. doi: 10.3324/haematol.2021.278841.

  69. NIETO Y, Gruschkus S, Valdez BC, Jones RB, et al
    Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.
    Haematologica. 2021 May 6. doi: 10.3324/haematol.2021.278311.
    PubMed     Abstract available

  70. RAMIS-ZALDIVAR JE, Gonzalez-Farre B, Nicolae A, Pack S, et al
    MAP-kinase and JAK-STAT pathways dysregulation in plasmablastic lymphoma.
    Haematologica. 2021 May 6. doi: 10.3324/haematol.2020.271957.
    PubMed     Abstract available

    April 2021
    Progress in understanding the biology of nodular lymphocyte predominant Hodgkin lymphoma.
    Haematologica. 2021 Apr 22. doi: 10.3324/haematol.2021.278785.
    PubMed     Abstract available

  72. PASCHOLD L, Willscher E, Bein J, Vornanen M, et al
    Evolutionary clonal trajectories in nodular lymphocyte predominant Hodgkin lymphoma with high transformation risk.
    Haematologica. 2021 Apr 22. doi: 10.3324/haematol.2021.278427.
    PubMed     Abstract available

  73. PICARDI M, Giordano C
    Comment on "Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study."
    Haematologica. 2021;106:1226-1227.

  74. BASTIDAS TORRES AN, Cats D, Out-Luiting JJ, Fanoni D, et al
    Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma.
    Haematologica. 2021 Apr 1. doi: 10.3324/haematol.2020.274506.
    PubMed     Abstract available

  75. MA MCJ, Tadros S, Bouska A, Heavican T, et al
    Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
    Haematologica. 2021 Apr 1. doi: 10.3324/haematol.2020.274258.
    PubMed     Abstract available

    March 2021
  76. VAJAVAARA H, Ekeblad F, Holte H, Jorgensen J, et al
    Prognostic impact of soluble CD163 in patients with diffuse large Bcell lymphoma.
    Haematologica. 2021 Mar 25. doi: 10.3324/haematol.2020.278182.
    PubMed     Abstract available

  77. ABEYKOON JP, Hampel PJ, King RL, Wood AJ, et al
    The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma.
    Haematologica. 2021 Mar 4. doi: 10.3324/haematol.2020.278277.
    PubMed     Abstract available

    February 2021
  78. DOBSON R, Du PY, Raso-Barnett L, Yao WQ, et al
    Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis.
    Haematologica. 2021 Feb 11. doi: 10.3324/haematol.2020.265991.
    PubMed     Abstract available

    Be mindful of the CNS in Burkitt lymphoma.
    Haematologica. 2021 Feb 4. doi: 10.3324/haematol.2020.278181.
    PubMed     Abstract available

  80. ZAYAC AS, Evens AM, Danilov A, Smith SD, et al
    Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multi-center cohort study.
    Haematologica. 2021 Feb 4. doi: 10.3324/haematol.2020.270876.
    PubMed     Abstract available

    Central nervous system prophylaxis in diffuse large B-cell lymphoma: a race to the bottom.
    Haematologica. 2021;106:332-334.

  82. BOBILLO S, Crespo M, Escudero L, Mayor R, et al
    Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas.
    Haematologica. 2021;106:513-521.
    PubMed     Abstract available

    January 2021
  83. KURTZ DM
    Bringing circulating tumor DNA to the clinic in Hodgkin lymphoma.
    Haematologica. 2021;106:5-6.

    December 2020
  84. ROSSI C, Tosolini M, Gravelle P, Pericart S, et al
    Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma.
    Haematologica. 2020;Online ahead of print:0.
    PubMed     Abstract available

  85. RAMAN L, Van der Linden M, De Vriendt C, Van den Broeck B, et al
    Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential.
    Haematologica. 2020;Online ahead of print:0.
    PubMed     Abstract available

    November 2020
  86. TANG T, Martin P, Somasundaram N, Lim C, et al
    Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or naturalkiller/T-cell lymphoma.
    Haematologica. 2020;Online ahead of print:0.
    PubMed     Abstract available

  87. RIEKE DT, Keller U
    A CD205-directed antibody drug conjugate - lymphoma precision oncology or sophisticated chemotherapy?
    Haematologica. 2020;105:2504-2506.

    October 2020
  88. ONG SY, Lim JQ, Grigoropoulos N, Laurensia Y, et al
    No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma.
    Haematologica. 2020;Online ahead of print.

  89. STEPHENS DM, Boucher K, Kander E, Parikh SA, et al
    Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.
    Haematologica. 2020;Online ahead of print.
    PubMed     Abstract available

    September 2020
  90. YOUSSEF Y, Karkhanis V, Chan WK, Jeney F, et al
    Transducin beta-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.
    Haematologica. 2020;Online ahead of print.
    PubMed     Abstract available

  91. MILLER PG, Sperling AS, Gibson CJ, Pozdnyakova O, et al
    A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade.
    Haematologica. 2020;Online ahead of print.

  92. MAURA F, Dodero A, Carniti C, Bolli N, et al
    CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).
    Haematologica. 2020;Online ahead of print.
    PubMed     Abstract available

    August 2020
  93. VOGELSBERG A, Steinhilber J, Mankel B, Federmann B, et al
    Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype.
    Haematologica. 2020 Aug 27. pii: haematol.2020.254854.
    PubMed     Abstract available

  94. ISAEV K, Ennishi D, Hilton L, Skinnider B, et al
    Molecular Attributes Underlying Central Nervous System and Systemic Relapse in Diffuse Large B-cell Lymphoma.
    Haematologica. 2020 Aug 13. pii: haematol.2020.255950.

  95. DERENZINI E, Mazzara S, Melle F, Motta G, et al
    A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma.
    Haematologica. 2020 Aug 13. pii: haematol.2019.236455.
    PubMed     Abstract available

  96. MATULIS SM, Boise LH
    BCL2 dependency in diffuse large B-cell lymphoma: it's a family affair.
    Haematologica. 2020;105:1993-1996.

    July 2020
  97. STRATI P, Varma A, Adkins S, Nastoupil LJ, et al
    Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.
    Haematologica. 2020 Jul 30. pii: haematol.2020.254045.
    PubMed     Abstract available

  98. THURNER L, Hartmann S, Bewarder M, Fadle N, et al
    Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B cell-type diffuse large B-cell lymphoma.
    Haematologica. 2020 Jul 16. pii: haematol.2019.241653.
    PubMed     Abstract available

  99. THORBALL CW, Oudot-Mellakh T, Ehsan N, Hammer C, et al
    Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma.
    Haematologica. 2020 Jul 16. pii: haematol.2020.247023.
    PubMed     Abstract available

    June 2020
  100. BERGER MD, Trelle S, Buchi AE, Jegerlehner S, et al
    Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma: a comprehensive meta-analysis.
    Haematologica. 2020 Jun 18. pii: haematol.2020.249680.
    PubMed     Abstract available

  101. LEE J, Kim B, Lee H, Park H, et al
    Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma.
    Haematologica. 2020;105:e458-460.

  102. MIYAZAKI K, Asano N, Yamada T, Miyawaki K, et al
    DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study.
    Haematologica. 2020;105:2308-2315.
    PubMed     Abstract available

  103. MINDERMAN M, Pals ST
    Towards genomic-based prognostication and precision therapy for diffuse large B-cell lymphoma.
    Haematologica. 2020;105:2194-2196.

  104. PIRIS MA
    Peripheral T-cell lymphoma diagnosis: building a molecular tool.
    Haematologica. 2020;105:1472-1474.

    May 2020
  105. TABANELLI V, Melle F, Motta G, Mazzara S, et al
    Evolutionary crossroads: morphological heterogeneity reflects divergent intra-clonal evolution in a case of high-grade B-cell lymphoma.
    Haematologica. 2020 May 28. pii: haematol.2020.249664.

  106. OISHI N, Hundal T, Phillips JL, Dasari S, et al
    Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma.
    Haematologica. 2020 May 15. pii: haematol.2019.245860.
    PubMed     Abstract available

  107. WANG Z, Gong Q, Zhao Y, Xu H, et al
    Indolent EBV-positive T-cell lymphoproliferative disorder arising in a chronic pericardial hematoma: the T-cell counterpart of fibrin-associated diffuse large B-cell lymphoma?
    Haematologica. 2020 May 15. pii: haematol.2020.252007.

  108. JACHIMOWICZ RD, Pieper L, Reinke S, Gontarewicz A, et al
    Analysis of the tumor microenvironment by whole-slide image analysis identifies low B cell content as a predictor of adverse outcome in advanced-stage classical Hodgkin lymphoma treated with BEACOPP.
    Haematologica. 2020 May 7. pii: haematol.2019.243287.
    PubMed     Abstract available

  109. MORSCHHAUSER F, Bouabdallah K, Stilgenbauer S, Thieblemont C, et al
    Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study.
    Haematologica. 2020 May 7. pii: haematol.2019.224535.

  110. SEYMOUR JF, Marcus R, Davies A, Gallop-Evans E, et al
    Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
    Haematologica. 2020;105:1465.

    April 2020
  111. LOGUE JM, Zucchetti E, Bachmeier CA, Krivenko GS, et al
    Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.
    Haematologica. 2020 Apr 23. pii: haematol.2019.238634.
    PubMed     Abstract available

  112. LAROSE H, Prokoph N, Matthews JD, Schlederer M, et al
    Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.
    Haematologica. 2020 Apr 23. pii: haematol.2019.238766.
    PubMed     Abstract available

  113. GERLACH MM, Stelling-Germani A, Wu CT, Newrzela S, et al
    SMAD1 promoter hypermethylation and lack of SMAD1 expression in Hodgkin lymphoma: a potential target for hypomethylating drug therapy.
    Haematologica. 2020 Apr 16. pii: haematol.2020.249276.

  114. MOSER O, Zimmermann M, Meyer U, Klapper W, et al
    Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group.
    Haematologica. 2020 Apr 16. pii: haematol.2019.244780.
    PubMed     Abstract available

  115. GARBIN A, Lovisa F, Holmes AB, Damanti CC, et al
    miR-939 acts as tumor suppressor by modulating JUNB transcriptional activity in pediatric anaplastic large cell lymphoma.
    Haematologica. 2020 Apr 16. pii: haematol.2019.241307.

  116. ARAF S, Korfi' K, Bewicke-Copley F, Wang J, et al
    Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma.
    Haematologica. 2020 Apr 9. pii: haematol.2019.242206.

  117. GARCIA-REYERO J, Martinez Magunacelaya N, Gonzalez de Villambrosia S, Loghavi S, et al
    Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.
    Haematologica. 2020 Apr 9. pii: haematol.2020.251579.
    PubMed     Abstract available

  118. WANG L, Tang G, Medeiros LJ, Xu J, et al
    MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma.
    Haematologica. 2020 Apr 9. pii: haematol.2019.243071.
    PubMed     Abstract available

  119. KERSTEN MJ, Driessen J, Zijlstra JM, Plattel WJ, et al
    Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
    Haematologica. 2020 Apr 9. pii: haematol.2019.243238.
    PubMed     Abstract available

  120. VAN DER MEULEN M, Bromberg JEC, Nijland M, Visser O, et al
    Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands.
    Haematologica. 2020 Apr 2. pii: haematol.2020.247536.

    March 2020
  121. SUZUKI T, Fukuhara S, Nomoto J, Yamashita S, et al
    Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors.
    Haematologica. 2020 Mar 26. pii: haematol.2019.235598.

  122. WANG Y, Tschautscher MA, Rabe KG, Call TG, et al
    Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.
    Haematologica. 2020;105:765-773.
    PubMed     Abstract available

    February 2020
  123. VITTORIO STEFONI, Miriam Marangon, Alessandro Re, Arben Lleshi, et al
    Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS.
    Haematologica. 2020;105:e512.

  124. MARITA ZIEPERT, Stefano Lazzi, Raffaella Santi, Federica Vergoni, et al
    A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients.
    Haematologica. 2020;105:2667-2670.

  125. GUILLAUME MANSON, Pauline Brice, Charles Herbaux, Kamal Bouabdallah, et al
    Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation.
    Haematologica. 2020;105:2664-2666.

    January 2020
  126. EUGENIO GAUDIO, Chiara Tarantelli, Filippo Spriano, Francesca Guidetti, et al
    Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.
    Haematologica. 2020;105:2584-2591.
    PubMed     Abstract available

  127. ANNARITA CONCONI, Catherine Thieblemont, Luciano Cascione, Valter Torri, et al
    Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment.
    Haematologica. 2020;105:2592-2597.
    PubMed     Abstract available

  128. BAILLY C, Carlier T, Kraeber-Bodere F, Le Gouill S, et al
    Reply to E. Laffon et al.
    Haematologica. 2020;105:e42.

  129. STRATI P, Nastoupil LJ, Davis RE, Fayad LE, et al
    A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.
    Haematologica. 2020;105:e26-e28.

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.